<html>
 <body>
  <div class="col-md-12" id="content" style="">
   <div class="hidden" data-drupal-messages-fallback="">
   </div>
   <div class="widget block" id="block-medsites-page-title">
    <h1>
     <span property="schema:name">
      Rheumatology Lab Testing
     </span>
    </h1>
   </div>
   <div class="widget block" id="block-medsites-content">
    <article about="/commodorecompendium/rheumatology-lab-testing" data-history-node-id="977" role="article" typeof="schema:WebPage">
     <div>
      <div class="field field--name-body field--type-text-with-summary field--label-hidden field__item" property="schema:text">
       <div class="WordSection1">
        <div style="border-bottom:solid windowtext 1.0pt; border-top:double windowtext 1.5pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
         <p style="border:none; padding:0in">
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <b>
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Rheumatology Lab Testing – Ben Boone
                </span>
               </span>
              </b>
             </span>
            </span>
           </span>
          </span>
         </p>
        </div>
        <ul>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Rheumatologic labs must be interpreted in the context of the clinical situation
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                It is challenging to interpret positive/abnormal labs with low pretest probability
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Sensitivities and specificities referenced below refer to scenarios with moderate-to-high probability clinical situations
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p style="margin-top:1px">
        </p>
        <p style="margin-top:1px">
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Rheumatoid Factor (RF)
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                A group of antibodies targeted against the Fc region of IgG
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                When positive in RA patients, called “seropositive RA” (typically more symptomatic)
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                A higher RF level is more specific for RA
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                70 - 80% sensitive for RA, but not very specific
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Present in 5-15% of healthy people
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Commonly positive in Sjogren’s, Mixed Connective Tissue Disease (MCTD), Mixed Cryoglobulinemia, SLE, and rarely inflammatory myopathies
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Can be positive some infectious diseases (i.e. malaria, hep B/C, rubella)
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Often positive in RA patients before Anti-CCP and even before symptoms/diagnosis
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Can be used as a surrogate when mixed cryoglobulinemia is suspected, since cryoglobulins can take up to a week to result and RF results in <48 hour
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
            <br/>
           </li>
          </ul>
         </li>
        </ul>
        <p style="margin-top:1px">
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Anti-cyclic Citrullinated Peptides (Anti-CCP)
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Very specific for RA (>95%); only 70% sensitive for RA
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                When positive in RA patients, called “seropositive RA” (typically more symptomatic)
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                A high titer is associated with more aggressive disease in RA
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p style="margin-top:1px">
        </p>
        <p style="margin-top:1px">
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Anti-nuclear Antibodies (ANA)
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Don't order for nonspecific symptoms – High Value Rheumatology Care Recommendation
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Should always be ordered with the reflex survey
                <b>
                 (ANA w/ Rfx ENA/DNA)
                </b>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Reported as both a titer and a pattern
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Titer
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
            <ul style="list-style-type:disc">
             <li>
              <span style="page:WordSection1">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    At VUMC, 1:80 is considered “positive”; however, a higher titer is more specific (albeit less sensitive) for ANA-associated rheumatologic disease
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </li>
             <li>
              <span style="page:WordSection1">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    ~30% of the general population has a “positive” ANA at 1:40, whereas only ~1% of people have a true ANA-associated rheumatologic disease
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </li>
            </ul>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Pattern
                 </span>
                </span>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  (three clinically significant ones)
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
            <ul style="list-style-type:disc">
             <li>
              <span style="page:WordSection1">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    Smooth/homogenous – associated with Anti-dsDNA and Anti-histone antibodies
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </li>
             <li>
              <span style="page:WordSection1">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    Speckled – associated with Anti-RNP, Anti-Smith, Anti-SSA/Ro, Anti-SSB/La
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </li>
             <li>
              <span style="page:WordSection1">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    Nucleolar – associated with Anti-Scl-70
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </li>
            </ul>
           </li>
          </ul>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                If ANA is
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style='font-family:"Arial",sans-serif'>
                ≥
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                1:80 the following studies will be sent:
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Anti-dsDNA (Quantitative and Qualitative)
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
            <ul style="list-style-type:disc">
             <li>
              <span style="page:WordSection1">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    Classical teaching is
                   </span>
                  </span>
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    anti-dsDNA antibodies are specific for SLE. However, this depends on lab methodology; VUMC uses ELISA assay (less specific)
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </li>
             <li>
              <span style="page:WordSection1">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    In some pts, dsDNA varies with disease activity
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </li>
             <li>
              <span style="page:WordSection1">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    If dsDNA is positive, there is an increased risk of renal lupus
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </li>
            </ul>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Positive
                 </span>
                </span>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  if
                  <u>
                   >
                  </u>
                  25 IU/mL ~70% sensitive and specific for SLE
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
        </ul>
        <ul>
         <li style="list-style-type:none">
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:list 28.1pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Anti-SSA/Ro (Qualitative)
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
            <ul style="list-style-type:disc">
             <li>
              <span style="page:WordSection1">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    Non-specific; ~70% sensitive for Sjogren’s; present in ~30% of SLE and MCTD pts
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </li>
             <li>
              <span style="page:WordSection1">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    Present in ~20% of RA and idiopathic inflammatory myopathy pts
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </li>
             <li>
              <span style="page:WordSection1">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    Maternal positivity for SSA is associated with congenital heart block in infants
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </li>
            </ul>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:list 28.1pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Anti-SSB/La (Qualitative)
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
        </ul>
        <ul>
         <li style="margin-left:10px">
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 37.45pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Similar profile to Anti-SSA/Ro but less common
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li style="margin-left:10px">
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 37.45pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 ~50% of Sjogren’s and ~20% of SLE/MCTD pts
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li style="margin-left:10px">
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 37.45pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Very rare to have Anti-SSB w/o Anti-SSA in a pt with true Sjogren’s disease
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li style="">
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:list 28.1pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Anti-Scl-70 (Qualitative)
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
            <ul style="list-style-type:disc">
             <li style="">
              <span style="page:WordSection1">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    Very specific for systemic sclerosis (>99%); 20-60% sensitive for systemic sclerosis
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </li>
             <li style="">
              <span style="page:WordSection1">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    ~70% sensitive for diffuse cutaneous systemic sclerosis
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </li>
             <li style="">
              <span style="page:WordSection1">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="font-family:Calibri,sans-serif">
                  <span style="font-size:12.0pt">
                   <span style="font-family:Palatino">
                    Only ~10% sensitive for CREST syndrome
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </li>
            </ul>
           </li>
           <li style="">
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:list 28.1pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Anti-Smith (Qualitative)
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
         <li style="margin-left:10px">
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 37.45pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Very specific >99% for SLE; but only ~20% sensitive for SLE
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li style="">
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:list 28.1pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Anti-RNP (Qualitative)
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
         <li style="margin-left:10px">
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 37.45pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Required for MCTD diagnosis; present in ~40% of SLE; rarely in systemic sclerosis
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p style="margin-top:1px">
        </p>
        <p style="margin-top:1px">
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Other notable ANAs
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Anti-histone: Associated w/drug-induced lupus (VUMC order:
                <b>
                 Histone IgG-ARUP
                </b>
                )
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Anti-centromere: Seen in limited scleroderma (CREST syndrome)
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Anti-neutrophil Cytoplasmic Antibodies (ANCA)
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:list 28.1pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Qualitative: p-ANCA, c-ANCA, negative, or indeterminate
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:list 28.1pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Quantitative titers: anti-proteinase 3 (PR3), anti-myeloperoxidase (MPO) IgG antibodies
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
        </ul>
        <p>
        </p>
        <p>
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               C3 and C4
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Complement
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                levels should be checked in any pt in whom you suspect active SLE
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Complement may also be low in diseases that decreases the liver’s synthetic function
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style='font-family:"Times New Roman",serif'>
                ↓
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                C3
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                /C4 in diseases that form immune complexes, activating the classic complement pathway: mixed cryoglobulinemia, Sjogren’s, MPGN, and antiphospholipid syndrome
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p style="margin-top:1px">
        </p>
        <p>
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               C-reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR)
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li style="list-style-type:none">
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:list 28.1pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Both tests are non-specific markers of inflammation
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:list 28.1pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Should be ordered alongside other rheumatology labs to corroborate disease activity
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                CRP
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                measures a specific protein made by the liver that activates the complement pathway
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:list 28.1pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   CRP is IL-6 dependent
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:list 28.1pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style='font-family:"Times New Roman",serif'>
                   ↓
                  </span>
                 </span>
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   IL-6 (pts on tocilizumab or tofacitinib) results in
                  </span>
                 </span>
                 <span style="font-size:12.0pt">
                  <span style='font-family:"Times New Roman",serif'>
                   ↓
                  </span>
                 </span>
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   CRP regardless of disease activity
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                ESR is the rate that RBCS settle in a standardized tube in one hour
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:list 28.1pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Fibrinogen is the primary driver of the ESR
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:list 28.1pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   The positive fibrinogen binds to the negatively-charged RBCs, allowing them to settle faster in the tube as RBCs no longer repel each other (both negatively charged)
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:list 28.1pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Both Low fibrinogen (DIC or HLH) and anemia falsely lower the ESR
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
        </ul>
        <p>
        </p>
        <p>
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Creatinine Kinase (CK)
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                CK can be elevated by exercise, rhabdomyolysis, endocrinopathy, cardiac disease, renal disease, malignancy, medication effect, neuromuscular disease, connective tissue disease
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:list 28.1pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Vigorous exercise can elevate CK up to 30-times the upper limit of normal
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                CK can be elevated in asymptomatic pts (should be rechecked in 1 wk to ensure resolution)
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Elevated
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                CK in pts with objective proximal muscle weakness can direct the differential diagnosis to inflammatory myopathies (dermatomyositis, inclusion body myositis, polymyositis, and immune-mediated necrotizing myopathy)
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:list 28.1pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Notably, CK is normal in polymyalgia rheumatica
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
        </ul>
        <p>
        </p>
       </div>
       <p>
       </p>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:normal">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="font-family:Palatino">
             Cryoglobulin Evaluation
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Clinical context drives interpretation of the test:
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 28.1pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 The presence of detectable cryoglobulins
                </span>
               </span>
               <span style="font-size:12.0pt">
                <span style='font-family:"Times New Roman",serif'>
                 ≠
                </span>
               </span>
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 cryoglobulinemic vasculitis
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Reported
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              as qualitative (positive or negative) and quantitative (percentage = “cryocrit”)
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 28.1pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 This test is highly prone to collection error
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 28.1pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 To perform this test, you need 6 full red-top tubes, kept between 37-39°C from the moment they are collected. This is accomplished using a thermos with a thermometer aka the “Cryo Kit”. At VUMC, this kit can be found in the immunopathology lab on the 4th floor. Place water at 39°C in the kit, then collect the blood at bedside with a nurse, placing each labeled tube directly into the water. Once all 6 tubes are collected, take the Cryo Kit back to the lab. If the temperature is less than 37°C, the lab won’t accept it
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Essential Cryoglobulinemia (rare ~ 10%): cryoglobulinemia w/o associated disease
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Cryoglobulinemic
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              vasculitis: small vessel vasculitis with a highly variable presentation
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul style="list-style-type:circle">
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 28.1pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Arthralgias, peripheral neuropathy and renal disease (usually MPGN) are common
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 28.1pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Skin involvement (purpura and erythematous macules, usually in colder areas of the body like the lower extremities)
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Type
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              I Cryoglobulins
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul style="list-style-type:circle">
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 28.1pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Monoclonal immunoglobulins (Igs); usually IgG or IgM; rarely IgA or light chains
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 28.1pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Classically associated with digital ischemia, skin necrosis, and livedo reticularis
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 28.1pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Associated with Waldenström macroglobulinemia, multiple myeloma, MGUS, and CLL
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Mixed Cryoglobulins (these do not produce a single monoclonal antibody like Type I)
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul style="list-style-type:circle">
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 28.1pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Type II
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
           <ul>
            <li>
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:list 37.45pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   A mixture of a monoclonal Ig (IgG, IgM, or IgA) combined with polyclonal Igs
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </li>
            <li>
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Associated with chronic viral infections HCV (most common), HBV, and HIV
                 </span>
                </span>
               </span>
              </span>
             </span>
            </li>
            <li>
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Less commonly seen in autoimmune diseases like SLE and Sjogren’s
                 </span>
                </span>
               </span>
              </span>
             </span>
            </li>
           </ul>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 28.1pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Type III
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
           <ul>
            <li>
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  A mixture of polyclonal IgG and polyclonal IgM
                 </span>
                </span>
               </span>
              </span>
             </span>
            </li>
            <li>
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:list 37.45pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Associated with the reverse profile of Type II; most commonly with autoimmune diseases; less commonly with infections
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </li>
           </ul>
          </li>
         </ul>
        </li>
       </ul>
       <p>
       </p>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:normal">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="font-family:Palatino">
             Extended Myositis Panel
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Can be sent when suspecting various forms of myositis such as dermatomyositis, polymyositis, anti-synthetase syndrome, etc.
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Ordered as “
              <b>
               Myositis extended Pnl-ARUP
              </b>
              ”
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul style="list-style-type:circle">
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 28.1pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Includes 19 separate antibodies with a summary interpretation provided at the end
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              P155 (TIF1-gamma) and P140 (NXP-2) antibodies are particularly associated with malignancy in pts > 30 y/o (ensure age-appropriate cancer screening)
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul>
          <li>
           <span style="font-size:12.0pt">
            <span style="line-height:107%">
             <span style="font-family:Palatino">
              PET/CT and pelvic U/S in female patients should be pursued to search for malignancy
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
       </ul>
      </div>
     </div>
    </article>
   </div>
  </div>
 </body>
</html>